These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 4522071)

  • 1. Side effects during intermittent rifampicin and ethambutol treatment. A preliminary report.
    Guerra Sanz FJ
    Scand J Respir Dis Suppl; 1973; 84():160-5. PubMed ID: 4522071
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical aspects of side effects on intermittent rifampicin regimen.
    Zierski M
    Scand J Respir Dis Suppl; 1973; 84():166-73. PubMed ID: 4522072
    [No Abstract]   [Full Text] [Related]  

  • 3. The intermittent chemotherapy of tuberculosis with rifampicin regimens on ambulatory basis.
    Anastasatu C; Bungeteanu G; Sibila S
    Scand J Respir Dis Suppl; 1973; 84():136-9. PubMed ID: 4522068
    [No Abstract]   [Full Text] [Related]  

  • 4. [Daily and intermittent regimens using ethambutol and rifampicin in the treatment of unresponsive cases. (Evaluation after 1 year.) II. Side effects].
    Girling DJ
    Bull Int Union Tuberc; 1974; 49(1):451-5. PubMed ID: 4619567
    [No Abstract]   [Full Text] [Related]  

  • 5. Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Clinical observations on adverse reactions.
    Girling DJ
    Scand J Respir Dis Suppl; 1973; 84():119-24. PubMed ID: 4522064
    [No Abstract]   [Full Text] [Related]  

  • 6. Side effects observed during intermittent rifampicin therapy.
    Stradling P
    Scand J Respir Dis Suppl; 1973; 84():129-31. PubMed ID: 4522066
    [No Abstract]   [Full Text] [Related]  

  • 7. Controlled clinical evaluation of three intermittent regimens employing low-dosage schedules of rifampicin in original treatment of pulmonary tuberculosis. Preliminary data on effectiveness and side effects.
    Nitti V
    Scand J Respir Dis Suppl; 1973; 84():180-5. PubMed ID: 4593266
    [No Abstract]   [Full Text] [Related]  

  • 8. Intermittent rifampicin treatment of tuberculosis.
    Riska N; Mattson K
    Scand J Respir Dis Suppl; 1973; 84():140-4. PubMed ID: 4522069
    [No Abstract]   [Full Text] [Related]  

  • 9. [Rifampicin combined with ethambutol and other antitubercular agents in the treatment of patients with chronic pulmonary tuberculosis. Early results. II. Analysis of causes of treatment interruption].
    Masztalerz J
    Pneumonol Pol; 1976 Feb; 44(2):153-61. PubMed ID: 940788
    [No Abstract]   [Full Text] [Related]  

  • 10. A trial of intermittent rifampicin and ethambutol in retreatment regimens.
    Zierski M
    Scand J Respir Dis Suppl; 1973; 84():132-5. PubMed ID: 4522067
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic effects and side effects of rifampicin administered daily or twice-weekly.
    Gomi J; Aoyagi T
    Scand J Respir Dis Suppl; 1973; 84():145-52. PubMed ID: 4522070
    [No Abstract]   [Full Text] [Related]  

  • 12. Preliminary results of a controlled therapeutic trail administering INH-RMP once-weekly, after--or without--an initial period of continuous treatment.
    Eule H; Kärnbach E; Kaluza P; Herrmann H
    Scand J Respir Dis Suppl; 1973; 84():153-9. PubMed ID: 4593264
    [No Abstract]   [Full Text] [Related]  

  • 13. [Proceedings: Preliminary results of a 2-phase therapy with rifampicin, ethambutol and a third drug in chronic polyresistant tuberculoses].
    Neumeyer D; Anschel R; Eule H; Fichtner K; Ganguin HG; Pickroth G
    Z Erkr Atmungsorgane Folia Bronchol; 1973; 138(1):135-8. PubMed ID: 4491710
    [No Abstract]   [Full Text] [Related]  

  • 14. Daily and intermittent short-course regimens in the original treatment of pulmonary tuberculosis. Preliminary results. Cooperative comparative clinical study in Poland.
    Zierski M
    Scand J Respir Dis Suppl; 1978; 102():48-52. PubMed ID: 278215
    [No Abstract]   [Full Text] [Related]  

  • 15. Intermittent chemotherapy of pulmonary tuberculosis using rifampicin and isoniazid for primary treatment: the influence of various factors on the frequency of side-effects.
    Eule H; Werner E; Winsel K; Iwainsky H
    Tubercle; 1974 Mar; 55(1):81-9. PubMed ID: 4620295
    [No Abstract]   [Full Text] [Related]  

  • 16. Haematological changes during intermittent treatment with rifampicin.
    Wislawska-Orlowska B; Pniewski T
    Scand J Respir Dis Suppl; 1973; 84():94-7. PubMed ID: 4522080
    [No Abstract]   [Full Text] [Related]  

  • 17. Proceedings of the Workshop on Intermittent Drug Therapy and Immunological Implications in Antituberculous Treatment with Rifampicin. Oct. 2-3, 1972 Stockholm. Organized by The Department of Thoracic Medicine, Karolinska Sjukhuset.
    Scand J Respir Dis Suppl; 1973; 84():1-193. PubMed ID: 4593267
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical effect of rifampicin-ethambutol isoniazid on untreated pulmonary tuberculosis.
    Konno K; Oizumi K; Yamada S; Ogata K; Sato M
    Sci Rep Res Inst Tohoku Univ Med; 1972 Sep; 19(2):68-72. PubMed ID: 4649624
    [No Abstract]   [Full Text] [Related]  

  • 19. [Rifampicin and ethanbutol in daily and intermittent treatment of chronic advanced cavernous pulmonary tuberculosis resistant to many drugs. Preliminary communication. Early results].
    Zierski M; Bek E; Kucharska A; Graczyk J; Bukalska Z
    Gruzlica; 1973 Nov; 41(11):1129-37. PubMed ID: 4765793
    [No Abstract]   [Full Text] [Related]  

  • 20. [A comparative study on clinical efficacy of rifampicin (RFP), ethambutol (EB) and ethionamide (1321 TH) in retreatment of pulmonary tuberculosis. Report of the 13th series study part B].
    Kekkaku; 1972 May; 47(5):139-44. PubMed ID: 5042532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.